GSK plc reports developments across its global biopharma business, including vaccines, respiratory medicines, infectious disease, immunology and oncology programs. Recurring updates include regulatory decisions and clinical evidence for products such as AREXVY, GSK's RSV vaccine, and Exdensur for severe asthma, along with data presentations, product indications and therapeutic-area access initiatives.
GSK news also covers manufacturing and supply agreements, commercial collaborations, public-health grant programs and product partnerships tied to its medicine and vaccine portfolio. As an American Depositary Share issuer, company updates may reflect both parent-company announcements and ADR-related market disclosures.
Summary not available.
GlaxoSmithKline's TUMS®, America’s leading heartburn brand, has launched a new campaign titled 'Love Food Back', aimed at encouraging consumers to embrace their favorite foods without fear of heartburn. This campaign pivots from a decade-long focus on combating heartburn to celebrating food enjoyment. The strategy includes interactive elements, such as the TUMS® Cam Sweepstakes, and features engaging advertisements showcasing humorous relationships between consumers and food. The campaign aims to redefine the emotional association with food and heartburn relief.
Pfizer announced plans to exit its 32% ownership interest in Haleon, the new standalone company formed post-GSK demerger. This move aims to maximize shareholder value. The demerger, involving GSK transferring approximately 80% of its consumer healthcare business to GSK shareholders, will be completed by July 2022. Haleon will also pursue a listing on the New York Stock Exchange. Key legal and financial advisors, including Morgan Stanley and Guggenheim Securities, are engaged in the process. This strategic decision aligns with Pfizer's focus on innovative medicines and vaccines.
GSK Consumer Healthcare has launched CareWalks, an initiative to support caregivers, in partnership with actress Jennie Garth. This program provides resources and encourages movement to alleviate pain associated with caregiving duties. Data reveals that 94% of caregivers report musculoskeletal pain, with many struggling to provide care due to this discomfort. The initiative includes a video series featuring caregivers' stories, email resources, and a charitable donation to Volunteers of America. Voltaren Arthritis Pain Gel is highlighted as a key product for managing osteoarthritis pain.
MOBItalks returns to New York on May 14, 2022, focusing on alternative wellness and community empowerment for Black gay men. Presented by ViiV Healthcare and the Mobilizing Our Brothers Initiative (MOBI), the event features speakers and provides networking opportunities. Attendees can enjoy free professional headshots and brunch by Cornbread26 Food Co. MOBI, active since 2017, aims to enhance personal development and community wellness, having contributed over $1 million to the Black queer community. For registration, visit mobi-nyc.com/nyctalks.
GlaxoSmithKline (GSK) has announced the acquisition of Sierra Oncology (SRRA) for $55 per share, totaling approximately $1.9 billion. This acquisition aims to enhance GSK’s portfolio in hematology, particularly through Sierra's drug momelotinib, which addresses the unmet medical needs of myelofibrosis patients suffering from anemia. GSK anticipates regulatory submissions in the US and EU shortly, with sales contributions expected to commence in 2023. The acquisition is projected to be accretive to GSK's adjusted EPS in 2024, supporting their long-term sales growth goals.
GSK's recent study indicates that individuals aged 50 and older diagnosed with COVID-19 face a significantly increased risk of developing shingles. The research, published in Open Forum Infectious Diseases, analyzed data from nearly 2 million Americans during March 2020 to February 2021. Key findings show a 15% higher likelihood of shingles post-COVID-19, with a 21% increase for those hospitalized. The study emphasizes the need for awareness and vaccination among older adults to mitigate risks associated with shingles following COVID-19.
ViiV Healthcare has received FDA approval for Cabenuva (cabotegravir, rilpivirine), the first long-acting HIV treatment specifically for virologically suppressed adolescents. The regimen allows for treatment as infrequent as six times a year, offering a crucial alternative to daily oral therapy. This approval highlights ViiV's commitment to addressing unmet needs in adolescent HIV care. The regimen's efficacy is supported by adult data and an interim analysis of the MOCHA study. However, adverse reactions were reported in 61% of adolescent participants, with injection site pain being the most common.
ViiV Healthcare announces US FDA approval for an updated label for Cabenuva, allowing treatment initiation directly with injections, bypassing the optional oral lead-in phase. This change enhances the user experience for HIV patients, streamlining the process of starting the first and only complete long-acting HIV treatment regimen. The label update is based on clinical trial results showing comparable safety and efficacy for both initiation methods. Cabenuva is indicated for virologically suppressed adults, reinforcing ViiV's commitment to innovative HIV therapies.
ViiV Healthcare announced the US FDA approval to update the label for Cabenuva, facilitating a streamlined initiation process for its long-acting HIV treatment. This update allows patients to start directly with injections, omitting the previously required oral lead-in regimen, after demonstrating comparable safety and efficacy between both initiation methods. Cabenuva, the only complete long-acting treatment for HIV-1, is approved for use in virologically suppressed adults. This approval is based on FLAIR trial results affirming effective treatment outcomes without the oral lead-in.